by Paul McIntosh | Oct 22, 2020 | Blog Post, Press Releases
By Grant Ellis, Director NovaBiotics Ltd On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will probably never disappear and a vaccine won’t stop it completely. He also said that ministers and experts...
by Paul McIntosh | Oct 16, 2020 | Press Releases
NovaBiotics secures £1 million in funding from Innovate UK to support clinical development of Nylexa for COVID-19 Aberdeen, 16 October 2020. NovaBiotics, the clinical stage antimicrobials drug discovery company, announces that it has secured £1 million in funding from...
by Paul McIntosh | Oct 12, 2020 | Press Releases, Uncategorized
NovaBiotics’ founder and Chief Executive Officer, Dr Deborah O’Neil FRSE, was amongst those recognised in the Queen’s 2020 Birthday Honours list. Deborah was made an Officer of the Most Excellent order of the British Empire (OBE) for services to biotechnology,...
by Paul McIntosh | Jul 7, 2020 | Press Releases
NovaBiotics are delighted to announce that our latest publication is accessible from today. Teamwork focused on solutions to antimicrobial resistance with our collaborators – Marcelo Der Torossian Torres, University of Pennsylvania Cesar de la Fuente, University...
by Paul McIntosh | Apr 13, 2020 | Press Releases
NovaBiotics, the clinical stage antimicrobials drug discovery company, announces the rapid repurposing of Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections. Nylexa ‘supercharges’ antibiotics, boosting their efficacy against...
by Paul McIntosh | Mar 31, 2020 | Press Releases
NovaBiotics announces its latest peer-reviewed publication describing data confirming the stand-out properties of Novexatin® (NP213), NovaBiotics’ brush-on treatment for fungal nail infection (onychomycosis). The paper, “NP213 (Novexatin®): A unique therapy candidate...
Contact Us
Technology
Therapeutic Focus
News and Events
Recent Comments